OverviewSuggest Edit

    AgilVax is a biotech company discovering and developing targeted antibody-based therapeutics for metastatic cancer. It offers an antibody-drug conjugate, xCT-ADC, that targets xCT (SLC7A11), an amino acid transporter, which exports glutamate in exchange for cystine, a precursor for the synthesis of the antioxidant glutathione, which normally protects cells from oxidative and chemical insults.

    Latest Updates

    Employees (est.) (Mar 2020)12

    Agilvax Financials and Metrics

    Summary Metrics

    Founding Date

    Show all financial metrics

    Agilvax Online and Social Media Presence

    Embed Graph

    Agilvax Frequently Asked Questions

    • When was Agilvax founded?

      Agilvax was founded in 2011.

    • How many employees does Agilvax have?

      Agilvax has 12 employees.

    • Who are Agilvax competitors?

      Competitors of Agilvax include Provectus Biopharmaceuticals, Mirati Therapeutics and Corvus Pharmaceuticals.